Britain must work with other countries to prevent friction on medicine rules post-Brexit to avoid being sidelined by the global drug industry, according to a report from the U.K.’s biggest pharmaceutical lobby group.

Two in three British pharmacies are struggling daily to source painkillers, cancer drugs and other vital medicines, research shows, as the availability of pharmaceuticals becomes increasingly uncertain.

President will put US firms first in UK trade talks, says Kim Darroch

Donald Trump is ready to use trade talks to force the National Health Service to pay more for its drugs as part of his scheme to "put American patients first”.

Inquiry hears of massive extra costs, a mountain of red tape, shrinking investment and chemicals ‘disappearing’ from UK market.

US pharmaceutical firms, known as Big Pharma, want 'full market access for US products' in the NHS which spends £140bn a year.

Sam Bright reports on the disruption, time and cost suffered by one mid-sized company before and after the UK’s formal departure from the European Union

Asked if Washington would be free to ‘jack up prices’, Foreign Secretary Dominic Raab replies ‘The Americans will take their decisions’.

‘No guidance’ has been issued since Chris Grayling’s notorious ferry contracts were axed – despite risk UK will crash out of EU in October. / Medical firms fear the political paralysis created by the Tory leadership race will leave the NHS short of essential drugs after a no-deal Brexit, because no proper planning is taking place.

Officials admit the Conservative leadership contest set back plans to secure enough medicines in the event of a no-deal outcome.

Brexit has been “a horrendous experience for Maltese businesses,” according to the CEO of the Malta Chamber of SMEs.

IN news which will surprise absolutely nobody, the Brexit talks are going terribly and pharmaceutical companies have been told to stockpile six week’s worth of drugs in case of disruption at the end of the transition period.

UK-US trade agreement was always going to be a tough sell. American Ambassador Woody Johnson’s comment to Andrew Marr on Sunday that healthcare would need to be on the table in any future trade talks only served to make agreeing a fully-fledged deal all the more difficult.

The government’s ‘serious shortage protocols’ are a real danger to the British public’s health – and may be illegal.

Sam Bright examines the contribution of Brexit to our current healthcare crisis.

An island nation must trade with its nearest mainland, whatever our new Brexit opportunities minister claims.

For almost 50 years, the NHS benefited from easy access to a large market, meaning it’s been first in the queue for the latest innovations. But what impact might Brexit have on medicines, medical devices and life sciences in the UK? Mark Dayan explains, in a blog that was first published in the BMJ on 26 February.

The impact of Brexit has only added fuel to the fire of severe challenges facing health and social care in the UK, warns the Nuffield Trust.

This note summarises the evidence so far of the impacts on Brexit on Scotland. It sets out early evidence related to areas such as trade, the workforce and EU programmes.

Six years after the referendum we can disentangle the evidence and judge the effects on health and care, says Richard Vize.

... the most hard-core Brexiters cannot articulate a deal that they prefer and has the slightest prospect of winning EU approval. Supporters of Brexit made incredible promises that had no basis in reality. / This matters greatly to Japan. Britain is the gateway to Europe for many Japanese companies. / Failure to reach a deal with the EU, for whatever reason, would be a disaster for the U.K.

But a closer inspection of the EU-UK Trade and Cooperation Agreement (TCA) renders these statements largely illusory for the pharma sector. While pharma companies grapple with the effects of Brexit, there are undoubtedly a number of ways that the TCA benefits the sector, while leaving significant issues unanswered.

The government and its supporters are beginning to claim 'benefits' of being outside the European Union some of which were always available to EU member states or, in other cases, are not benefits at all.